Drug Profile

NVD 003

Alternative Names: NVD-003

Latest Information Update: 30 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Novadip Biosciences
Class Stem cell therapies
Mechanism of Action Angiogenesis inducing agents; Cell replacements; Osteogenesis stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Pseudoarthrosis
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase I/II Non-union fracture; Pseudoarthrosis

Most Recent Events

23 Jun 2025 Novadip Biosciences plans to launch NVD 003 for Pseudoarthrosis in 2025
23 Jun 2025 NVD 003 receives Regenerative Medicine Advanced Therapy (RMAT) status for Pseudoarthrosis in USA
23 Jun 2025 Novadip Biosciences plans a phase III trial for Pseudoarthrosis in USA and Europe, in June 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com